Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPIA | P62937 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158405 | 0.92 | PTGER1 (0.48) | PTGER1CYP2C9MEN1KMT2APPIA | |
| SCHEMBL4146526 | 0.91 | PTGER1 (0.60) | PTGER1CYP2C9MEN1KMT2ACNR1 | |
| SCHEMBL4158531 | 0.91 | PTGER1 (0.50) | PTGER1CYP2C9KMT2APPIACNR1 | |
| SCHEMBL4150652 | 0.85 | PTGER1 (0.47) | PTGER1CYP2C9CNR1 | |
| SCHEMBL4146738 | 0.83 | PTGER1 (0.59) | PTGER1CYP2C9CNR1 | |
| SCHEMBL4162911 | 0.82 | PTGER1 (0.58) | PTGER1CYP2C9CNR1 | |
| SCHEMBL5621868 | 0.80 | PTGER1 (0.67) | PTGER1CYP2C9 | |
| SCHEMBL13696916 | 0.80 | PTGER1 (0.49) | PTGER1CYP2C9PPIAMAPTALDH1A1 | |
| SCHEMBL4163918 | 0.79 | PTGER1 (0.50) | PTGER1CYP2C9CNR1 | |
| SCHEMBL5621576 | 0.79 | PTGER1 (0.62) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885MEN1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.